Hybio Pharmaceutical secures 700m yuan financing to boost operations

Hybio Pharmaceutical announced on October 22, 2025, that its board approved a resolution to secure financing from Shenzhen Hi-Tech Investment Group and its subsidiaries. The total financing amount will not exceed 700 million yuan, covering multiple products, with a term not exceeding 12 months.

The financing will be secured by collateral from the company's Pingshan branch and a portion of the assets of its Dali subsidiary, as per the terms of the signed contracts. The company's board has authorized the chairman or their representative to execute relevant documents and utilize the credit line based on funding requirements.

Shenzhen Hi-Tech Investment Group, established on December 29, 1994, with a registered capital of 15,920,957,914 yuan, specializes in guarantee services, investment development, information consulting, loan guarantees, and property leasing. The announcement clarifies that there are no related party transactions between Hybio Pharmaceutical and Shenzhen Hi-Tech Investment Group.